BioLineRx Ltd.'s BL-8040 Receives Orphan Drug Designation for Treatment of ... Lifescience-online Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. BL-8040 was licensed by BioLineRx from ... |
